PIVOT-02: A phase 1/2, open-label, multicenter, dose escalation and dose expansion study of NKTR-214 and nivolumab in patients with select, locally advanced or metastatic solid tumor malignancies

被引：0
|
作者：
Diab, A. [1 ]
Hurwitz, M. E. [2 ]
Tannir, N. [3 ]
Bernatchez, C. [1 ]
Haymaker, C. [1 ]
Bentebibel, S. E. [1 ]
Curti, B. D. [4 ,5 ]
Wong, M. K. K. [1 ]
Gergel, I. [6 ]
Tagliaferri, M. [7 ]
Zalevsky, J. [8 ]
Hoch, U. [9 ]
Aung, S. [7 ]
Imperiale, M. [7 ]
Cho, D. [10 ]
Tykodi, S. S. [11 ,12 ]
Puzanov, I. [13 ]
Kluger, H. [14 ]
Hwu, P. [1 ]
Sznol, M. [15 ]
机构：
[1] MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Houston, TX USA
[2] Yale Sch Med, Div Med Oncol, Dept Internal Med, New Haven, CT USA
[3] MD Anderson Canc Ctr, Genitourinary Med Oncol, Houston, TX USA
[4] Providence Canc Ctr, Dept Genitourinary Oncol Res, Portland, OR USA
[5] Earle A Chiles Res Inst, Portland, OR USA
[6] Nektar Therapeut, Dept Drug Dev, San Francisco, CA USA
[7] Nektar Therapeut, Dept Clin Dev, San Francisco, CA USA
[8] Nektar Therapeut, Dept Biol & Preclin Dev, San Francisco, CA USA
[9] Nektar Therapeut, Dept Clin Pharmacol, San Francisco, CA USA
[10] Dept Med Oncol, NYU Med Oncol Associates, New York, NY USA
[11] Univ Washington, Dept Med Oncol, Seattle, WA 98195 USA
[12] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA
[13] Roswell Pk Canc Inst, Dept Med Oncol, Buffalo, NY 14263 USA
[14] Yale Breast Ctr, Dept Med Oncol, New Haven, CT USA
[15] Yale Univ, Dept Med Oncol, Sch Med Med Oncol, New Haven, CT USA
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1212TiP
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Phase 1b/2, open-label, multicenter, dose escalation and expansion trial of intratumoral SD 101 in combination with pembrolizumab in patients with metastatic melanoma
    Ribas, A.
    Gonzalez, R.
    Drabick, J.
    Kummar, S.
    Agarwala, S.
    Nemunaitis, J.
    Coffman, R.
    Berman, C. J.
    Schmidt, E.
    Chartash, E.
    Guiducci, C.
    Candia, A.
    Janssen, R.
    ANNALS OF ONCOLOGY, 2016, 27
  • [32] A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY AND TOLERABILITY STUDY OF NC762 IN SUBJECTS WITH ADVANCED OR METASTATIC SOLID TUMORS
    Myint, Han
    Shah, Satish
    Gutierrez, Martin
    Zsiros, Emese
    Nelson, Megan
    Zeidan, Stephanie
    Myrthil, Nadia
    Morawski, Aaron
    Barbu, Alina
    Shaik, Jahangheer
    Zhou, Chelsea
    Kanellopoulou, Chrysi
    Copeland, Ron
    Cusumano, Zachary
    Flies, Dallas
    Langermann, Solomon
    Lorusso, Patricia
    Odunsi, Kunle
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A781 - A781
  • [33] A Phase I, Open-Label, Dose Confirmation, Escalation, and Expansion Trial of BI 1810631 as Monotherapy in Patients With Advanced or Metastatic Solid Tumors With HER2 Aberrations
    Heymach, John
    Opdam, Frans
    Barve, Minal
    Gibson, Neil
    Sadrolhefazi, Behbood
    Serra, Josep
    Yamamoto, Noboru
    CLINICAL LUNG CANCER, 2023, 24 (02) : e65 - e68
  • [34] A phase I, open-label, dose escalation, confirmation, and expansion trial of BI 1810631 as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations
    Opdam, F.
    Heymach, J.
    Barve, M.
    Gibson, N.
    Sadrolhefazi, B.
    Serra, J.
    Yamamoto, N.
    ANNALS OF ONCOLOGY, 2022, 33 : S69 - S70
  • [35] Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive malignancies: an open-label, multicentre, phase 1, dose-escalation and dose-expansion study
    Fischer, Matthias
    Moreno, Lucas
    Ziegler, David S.
    Marshall, Lynley, V
    Zwaan, C. Michel
    Irwin, Meredith S.
    Casanova, Michela
    Sabado, Constantino
    Wulff, Beate
    Stegert, Mario
    Wang, Luojun
    Hurtado, Felipe K.
    Branle, Fabrice
    Geoerger, Birgit
    Schulte, Johannes H.
    LANCET ONCOLOGY, 2021, 22 (12): : 1764 - 1776
  • [36] PIVOT-09: A phase III randomized open-label study of bempegaldesleukin (NKTR-214) plus nivolumab versus sunitinib or cabozantinib (investigator's choice) in patients with previously untreated advanced renal cell carcinoma (RCC)
    Tannir, Nizar M.
    Agarwal, Neeraj
    Pal, Sumanta K.
    Cho, Daniel C.
    Formiga, Maria
    Guo, Jun
    George, Daniel J.
    Tagliaferri, Mary Ann
    Singel, Stina Mui
    O'Keeffe, Bridget A.
    Hannah, Alison L.
    Balbas, Minna
    Penkov, Konstantin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [37] Phase I dose-escalation, open-label study of HSP990 administered orally in adult patients with advanced solid malignancies.
    De Mattos-Arruda, Leticia
    Siu, Lillian L.
    Cortes, Javier
    Berge, Yann
    Razak, Albiruni R. A.
    Ahnert, Jordi Rodon
    Cottura, Ewa
    Bedard, Philippe
    Akimov, Mikhail
    Lu, Hong
    Pain, Scott
    Kaag, Audrey
    Delord, Jean-Pierre
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [38] A phase 1/2, open-label, dose-escalation, safety and tolerability study of NC410 in subjects with advanced or metastatic solid tumors.
    Gutierrez, Martin
    Janku, Filip
    Tian, Linjie
    Luke, Jason J.
    Shum, Elaine
    Shin, John
    Weiss, Ido
    Liu, Linda N.
    Files, Dallas
    Langermann, Solomon
    Myint, Han
    Bilusic, Marijo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [39] Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States
    Andrea Wang-Gillam
    William Schelman
    Stacey Ukrainskyj
    Caly Chien
    Martha Gonzalez
    Zhao Yang
    Marek Kania
    Heather Yeckes-Rodin
    Investigational New Drugs, 2023, 41 (6) : 851 - 860
  • [40] Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States
    Wang-Gillam, Andrea
    Schelman, William
    Ukrainskyj, Stacey
    Chien, Caly
    Gonzalez, Martha
    Yang, Zhao
    Kania, Marek
    Yeckes-Rodin, Heather
    INVESTIGATIONAL NEW DRUGS, 2023, 41 (06) : 851 - 860
12345